QoL of patients with R/R Hodgkin lymphoma treated with pembrolizumab vs brentuximab vedotin
0 Views
administrator
07/09/23
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, comments on the findings of a study comparing the quality of life (QoL) of patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (HL) treated with pembrolizumab vs brentuximab vedotin. The study demonstrated that pembrolizumab was more effective and better tolerated than brentuximab vedotin. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
-
Category
Show more
Facebook Comments
No comments found